Table 1 Baseline characteristics of the population of the cohort.

From: Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs

Characteristic

Healthy controls (n = 15) (A)

HCV-infected patients

p

Global (n = 86) (B)

HCV monoinfected patients (n = 20) (C)

HIV/HCV coinfected patients (n = 66) (D)

A versus B

A versus C

A versus D

C versus D

Male sex [n (%)]

10 (67)

63 (73)

8 (35)

58 (88)

0.831

0.222

0.103

< 0.001

Age (years), median (IQR)

55 (48–61)

55 (51–59)

60 (56–67)

54 (50–56)

0.230

0.195

0.299

< 0.001

PWID

 

35 (41)

1 (5)

34 (52)

   

< 0.001

HCV genotype [n (%)]

       

0.001

1a

 

25 (28)

1 (5)

24 (36)

    

1b

 

28 (33)

14 (70)

14 (22)

    

2

 

0 (0)

0 (0)

0 (0)

    

3

 

12 (14)

3 (15)

9 (14)

    

4

 

18 (21)

1 (5)

17 (26)

    

Mixed 1a + 1b

 

3 (4)

1 (5)

2 (3)

    

Active and excessive alcohol consumption [n (%)]

 

9 (11)

1 (5)

8 (12)

   

0.001

Treatment-experienced (Peg-IFN-based regimens) [n (%)]

 

31 (36)

4 (20)

27 (41)

   

0.114

HCV viral load (log UI/l), median (IQR)

 

6.0 (5.2–6.4)

5.6 (4.9–6.2)

6.1 (5.4 – 6.5)

   

0.046

AST (IU/l), median (IQR)

 

48 (30–71)

38 (29–62)

49 (31–74)

   

0.288

ALT (IU/l), median (IQR)

 

46 (33–82)

46 (27–91)

46 (34–80)

   

0.931

Baseline liver stiffness, median (IQR)

 

11.1 (8.8–20.1)

8.7 (4.7–11.5)

12.7 (9.3–26.3)

   

0.001

Baseline fibrosis stage [n (%)]

       

0.001

Non-significant fibrosis (F0–F1)

 

13 (15)

8 (40)

5 (8)

    

Significant fibrosis (F2–F3)

 

41 (48)

8 (40)

33 (50)

    

Cirrhosis (F4)

 

32 (37)

4 (20)

28 (42)

    

AST to Platelet Ratio Index (APRI), median (IQR)

 

0.95 (0.51–1.97)

0.46 (0.39–0.83)

1.11 (0.59–2.76)

   

0.002

Fibrosis-4 (FIB-4) score, median (IQR)

 

2.12 (1.54–4.74)

1.56 (1.29–2.00)

2.36 (1.71–5.63)

   

0.006

Prior liver decompensation [n (%)]

 

4 (5)

0 (0)

4 (6)

   

1.000

Platelets/mm3  × 1000, median (IQR)

235 (210–262)

157 (102–212)

210 (183–247)

141 (92–186)

< 0.001

0.178

< 0.001

< 0.001

Lymphocites/mm3, median (IQR)

2123 (1645–2514)

1908 (1404–2433)

2062 (1523–2261)

1890 (1388–2447)

0.257

0.865

0.212

0.871

CXCL4 (ng/ml), median (IQR)

6425 (4743–9599)

3002 (1435–5894)

2291 (1465–5079)

3174 (1435–6119)

0.002

0.003

0.003

0.649

TGF-β1 (pg/ml), median (IQR)

39,989 (35,356–57,606)

17,797 (11,502–29,674)

20,958 (14,928–37,717)

15,968 (11,068–24,496)

< 0.001

 < 0.001

 < 0.001

0.079

HGF (pg/ml), median (IQR)

2803 (2294–3111)

4549 (3043–6784)

2738 (1568–4564)

4833 (3488–8394)

 < 0.001

0.987

 < 0.001

 < 0.001

DAA treatment regimens [n (%)]

       

 < 0.001

Sofosbuvir/ledipasvir

 

44 (51)

6 (30)

38 (58)

    

Sofosbuvir/simeprevir

 

2 (2)

0 (0)

2 (3)

    

Sofosbuvir/daclastasvir

 

9 (11)

0 (0)

9 (14)

    

Sofosbuvir/velpatasvir

 

4 (5)

3 (15)

1 (2)

    

Ombitasvir/paritaprevir/ritonavir/dasabuvir

 

21 (25)

7 (35)

14 (22)

    

Ombitasvir/paritaprevir/ritonavir

 

2 (2)

0 (0)

2 (3)

    

Elbasvir/grazoprevir

 

4 (5)

4 (20)

0 (0)

    
  1. HCV hepatitis C virus, HIV human immunodeficiency virus, IQR interquartile range, PWID people who inject drugs, AST aspartate amino-transferase, ALT alanine amino-transferase, CXCL4 chemokine (C-X-C motif) ligand 4, TGF-β1 transforming growth factor β1, HGF hepatocyte growth factor, DAA directed antiviral (anti-HCV) agents.
Back to article page